© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 91306 refers to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, specifically designed to combat coronavirus disease (COVID-19). This vaccine utilizes a novel approach by employing messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), which is a cutting-edge technology in vaccine development. The mRNA contained in this vaccine encodes the spike protein of the SARS-CoV-2 virus, which is critical for the virus's ability to infect human cells. Upon administration, the mRNA instructs the body's cells to produce copies of the spike protein, which the immune system identifies as foreign. This triggers an immune response, leading to the production of antibodies that can recognize and neutralize the virus if the individual is exposed in the future. The vaccine is preservative-free and is administered in a dosage of 50 mcg per 0.25 mL via intramuscular injection. It is important to note that this code specifically reports the supply of Moderna's lower-dose vaccine product, which is intended for use as a booster for individuals aged 18 and older who have already received the initial Moderna vaccine. The administration of the vaccine itself is reported separately using the appropriate administration code, ensuring accurate billing and documentation for healthcare providers.
© Copyright 2025 Coding Ahead. All rights reserved.
The CPT® Code 91306 is indicated for the administration of the SARS-CoV-2 vaccine to provide immunity against COVID-19. The following conditions and circumstances warrant the use of this vaccine:
The administration of the CPT® Code 91306 vaccine involves several key procedural steps, which are outlined as follows:
Following the administration of the CPT® Code 91306 vaccine, patients are advised to remain in the healthcare setting for a brief observation period to monitor for any immediate side effects or allergic reactions. Common post-vaccination care includes advising patients to rest and hydrate adequately. They should also be informed about potential side effects, which may include soreness at the injection site, fatigue, headache, or mild fever. Patients should be encouraged to report any unusual or severe reactions to their healthcare provider. Additionally, it is important to remind patients of the need for follow-up vaccinations if applicable, and to continue practicing preventive measures against COVID-19, such as wearing masks and social distancing, until they are fully vaccinated and protected.
Short Descr | SARSCOV2 VAC 50MCG/0.25ML IM | Medium Descr | SARSCOV2 VACCINE 50 MCG/0.25 ML IM USE | Long Descr | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use | Status Code | Not Valid for Medicare Purposes | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Non-Covered Service, not paid under OPPS | Berenson-Eggers TOS (BETOS) | none | MUE | Not applicable/unspecified. |
SL | State supplied vaccine |
Date
|
Action
|
Notes
|
---|---|---|
2025-01-01 | Deleted | First appearance of code deletion in codebook. |
2024-01-01 | Note | First appearance of 2022 guideline updates to codebook. |
2023-11-01 | Deleted | Code deleted. See 91318, 91319, 91320, 91321, 91322. |
2023-04-18 | Note | Changes made to dosing information |
2023-04-18 | Note | These codes (included in the guidelines) are no longer authorized for use in the United States: 0011A, 0012A, 0013A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A. |
2023-04-18 | Note | AMA guidelines changed to include 0141A, & 0142A. Published to website 2023-05-01. Received FDA approval effective retroactively to 2023-04-18. |
2023-04-18 | Note | No longer authorized for use in the United States. |
2023-01-01 | Added | First appearance in codebook. |
2023-01-01 | Note | First appearance of guideline change(s) in codebook. |
2022-12-08 | Note | AMA Guideline changed. 0164A received FDA approval. |
2022-11-16 | Note | AMA guideline changed to include 0164A effective upon receiving Emergency Use Authorization or approval from the FDA |
2022-10-12 | Note | AMA Guideline changed. 0134A(12–17 yrs) and 0144A received FDA approval. |
2022-08-31 | Note | Changes made to vaccine name, product & dosing information, & patient age to (18+). |
2022-08-31 | Note | AMA Guideline changed. 0134A(18 yrs and older) received FDA approval effective immediately. |
2022-08-31 | Note | AMA guideline changed to include 0134A, 0144A effective upon receiving emergency Use Authorization or approval from the FDA. |
2022-06-17 | Note | AMA guideline changed to include 0091A, 0092A, 0093A, 0113A added to website 2022-07-06. FDA approval received. Effective retroactively to 2022-06-17. |
2022-06-17 | Note | AMA Guideline changed. 0111A, 0112A received FDA approval |
2022-05-19 | Note | New AMA guideline added. Codes 0111A & 0112A Published to website. Effective upon receiving Emergency Use Authorization or approval from the FDA |
2022-05-19 | Note | New AMA guideline added. Codes 0011A, 0012A, 0013A added to website & received FDA approval prior to the addition of this new guideline. |
2022-03-29 | Note | AMA Guideline changed. 0094A received FDA approval. |
2022-03-07 | Note | AMA guideline changed to include 0094A effective upon receiving Emergency Use Authorization or approval from the FDA. |
2021-10-20 | Added | FDA approval received. |
2021-10-20 | Note | AMA Guideline changed. 0064A received FDA approval. |
2021-09-03 | Note | AMA guideline includes 0064A effective upon receiving Emergency Use Authorization or approval from the FDA. |
2021-09-03 | Added | Published on AMA website. Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration. |
Get instant expert-level medical coding assistance.